Revive Therapeutics Ltd.
RVV.CN
Canadian Securities Exchange0.03
CAD
- -
- -
Revive Therapeutics Ltd.
RVV.CN
(Canadian Securities Exchange)
Recent
price
0.03
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- Revive Therapeutics Ltd. is a clinical-stage pharmaceutical company primarily engaged in the development and commercialization of therapeutics for rare and infectious diseases, as well as mental health disorders. The company’s core product portfolio includes psychedelic-based therapeutics and conventional pharmaceuticals, focusing on the development of treatments such as psilocybin for mental health conditions including depression and anxiety; Bucillamine as a potential treatment for COVID-19 and other infectious diseases; and other novel small molecule drugs. Revive Therapeutics’ key services encompass clinical trial management, drug development, and regulatory affairs focused on advancing its innovative drug pipeline. The company operates mainly in North America, with research and development activities headquartered in Toronto, Canada, where it was founded in 2015. Recent major company developments include strategic partnerships and collaborations to advance clinical trials of its psychedelic and pharmaceutical assets, expanded research into novel infectious disease treatments highlighted by recent clinical studies on Bucillamine, and the launch of new product development initiatives targeting both mental health and infectious disease markets. In the last 1-2 years, the company has made significant progress in regulatory approvals and trial milestones that underscore its strategic shift toward psychedelic-assisted medicine and rare disease therapeutics. Additionally, Revive Therapeutics has secured new funding rounds to accelerate its clinical pipeline and expand its operational capabilities. No recent name change or reorganization has been reported. Revive Therapeutics operates within the pharmaceutical and biotechnology industry, specifically within the segments of mental health, rare diseases, and infectious disease drug development. Its target markets include healthcare providers, pharmaceutical distributors, and research institutions primarily across Canada and the United States. The company’s emphasis on psychedelic medicine and innovative infectious disease therapeutics positions it at the forefront of contemporary pharmaceutical research and development with a growing focus on clinical-stage and near-market readiness of its product candidates. This comprehensive scope of products, strategic developments, and geographic focus defines Revive Therapeutics Ltd. as a specialized clinical-stage pharmaceutical entity dedicated to advancing novel therapies for significant unmet medical needs.